علاج سرطان الخلايا القاعدية الجلدي المتقدم موضعياً

References

1. Advanced BCC includes locally advanced BCC (laBCC) and metastatic BCC (mBCC).
2. Anti-PD1 immunotherapy should be offered as second-line treatment in patients who progress or have contraindications to hedgehog inhibitors.
3. Eighty-four laBCC patients received cemiplimab with the conventional dose of 350 mg intravenously every 3 weeks for up to 93 weeks or until progression or unacceptable toxicity.